Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447834 | 1.00 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3853492 | 1.00 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL5378432 | 1.00 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL2454978 | 1.00 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL7576302 | 0.92 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL5546188 | 0.92 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL8081055 | 0.92 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL1863581 | 0.86 | — | — | |
| SCHEMBL10346067 | 0.80 | — | — | |
| SCHEMBL8358120 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053939-B1 | ACRYLIC-MODIFIED, PB-CURABLE COMPOSITION HAVING EXCELLENT LIGHT RESISTANCE AND EXCEPTIONAL MECHANICAL STRENGTH | NIPPON SODA CO (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20160229942-A1 | ACRYLIC-MODIFIED, PB-CURABLE COMPOSITION HAVING EXCELLENT LIGHT RESISTANCE AND EXCEPTIONAL MECHANICAL STRENGTH | NIPPON SODA CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3053939-A1 | ACRYLIC-MODIFIED, PB-CURABLE COMPOSITION HAVING EXCELLENT LIGHT RESISTANCE AND EXCEPTIONAL MECHANICAL STRENGTH | Nippon Soda Co., Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150274863-A1 | POLYBUTADIENE DERIVATIVE COMPOSITION | NIPPON SODA CO (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2620455-B1 | METHOD FOR PRODUCING TERMINAL ACRYLIC-MODIFIED POLYBUTADIENE OR TERMINAL ACRYLIC-MODIFIED HYDROGENATED POLYBUTADIENE, AND COMPOSITION CONTAINING SAME | NIPPON SODA CO (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2476710-B1 | METHOD FOR PRODUCING POLYBUTADIENE | NIPPON SODA CO (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8822600-B2 | Method for producing terminal acrylic-modified polybutadiene or terminal acrylic-modified hydrogenated polybutadiene, and composition containing same | NIPPON SODA CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140005317-A1 | POLYBUTADIENE DERIVATIVE COMPOSITION | NIPPON SODA CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2620455-A1 | METHOD FOR PRODUCING TERMINAL ACRYLIC-MODIFIED POLYBUTADIENE OR TERMINAL ACRYLIC-MODIFIED HYDROGENATED POLYBUTADIENE, AND COMPOSITION CONTAINING SAME | Nippon Soda Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20130165586-A1 | METHOD FOR PRODUCING TERMINAL ACRYLIC-MODIFIED POLYBUTADIENE OR TERMINAL ACRYLIC-MODIFIED HYDROGENATED POLYBUTADIENE, AND COMPOSITION CONTAINING SAME | NIPPON SODA CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20120289638-A1 | POLYBUTADIENE DERIVATIVE COMPOSITION | NIPPON SODA CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120202910-A1 | METHOD FOR PRODUCING POLYBUTADIENE | NIPPON SODA CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2476710-A1 | METHOD FOR PRODUCING POLYBUTADIENE | Nippon Soda Co., Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289638-A1 | POLYBUTADIENE DERIVATIVE COMPOSITION | MMAB, MAT2B, HBB | ALDH1A1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.